ERBB2 and breast cancer: Indeed, patients harboring CD16 158 V NK cells show a better clinical response after rituximab (an antibody targeting CD20) treatment [124] and in trastuzumab (an antibody targeting HER2)-treated HER2+ breast cancer patients [125].